The short answer
A hypoglycaemia rate depends on what else participants were taking, what glucose threshold was used to define an event, and how far HbA1c fell. All three move the number substantially, sometimes more than the compound does.
Key facts
- Factor 1
- Background therapy
- Factor 2
- Threshold defining an event
- Common threshold
- Glucose below 54 mg/dL, or severe
- Factor 3
- Magnitude of HbA1c reduction
- SURPASS-4 illustration
- 1-3% vs 6-9%, same compound
- Difference explained by
- Sulfonylurea use
Background therapy moves it most
SURPASS-4 shows this directly. Hypoglycaemia occurred in 6 to 9% of tirzepatide participants overall, but in only 1 to 3% of those not taking a sulfonylurea. Same compound, same trial, same definition, and a several-fold difference produced entirely by what else was being taken.
The threshold is a choice, not a fact
SURPASS-4 counted events at glucose below 54 mg/dL or clinically severe. A trial using a higher threshold counts more events; one requiring assistance from another person counts far fewer. Rates from trials using different definitions are not comparable, and the definition is frequently omitted from summaries.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
How far glucose fell matters too
An agent lowering HbA1c further moves participants closer to the lower end of the range, where an ordinary fluctuation is more likely to cross a threshold. Some hypoglycaemia risk therefore tracks the effectiveness of glucose lowering rather than the mechanism producing it, which is the same pattern as retinopathy and rapid HbA1c reduction elsewhere on this site.
Why the comparator determines what the number means
Against placebo, an incretin will show more hypoglycaemia than nothing. Against insulin, considerably less. SURPASS-4 reported 19% with glargine against 6 to 9% with tirzepatide. Both comparisons are true and they support opposite-sounding statements, which is why the comparator belongs in any quoted figure.
The question to ask of any rate
On what background, by what definition, against what comparator, and at what degree of glucose lowering. A figure travelling without those four is not interpretable, and hypoglycaemia rates travel without them more often than most safety numbers.
What none of this is
Guidance. It describes how to read published trial data about licensed medicines given under clinical supervision. Nothing supplied on this site affects blood glucose, and decisions about diabetes treatment belong with a clinician.
Frequently asked questions
What moves a hypoglycaemia rate most?
Background therapy. In SURPASS-4 the same compound showed 1-3% without a sulfonylurea and 6-9% overall.
Is the threshold standardised?
No. SURPASS-4 used glucose below 54 mg/dL or severe. Other thresholds count more or fewer events, making rates non-comparable.
Can effective glucose lowering itself raise the rate?
Yes. Moving closer to the lower end of the range makes ordinary fluctuation more likely to cross a threshold.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDel Prato S et al., Tirzepatide versus insulin glargine (SURPASS-4). Lancet 2021 (PMID 34672967)pubmed.ncbi.nlm.nih.gov
- PubMedFilippatos TD et al., Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 2014 (PMID 26177483)pubmed.ncbi.nlm.nih.gov
- PubMedVilsbøll T et al., Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2018 (PMID 29178519)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What the Class Reliably ProducesGastrointestinal effects dominate and follow from the mechanism. A 2014 review set out the profile before the current generation existed.
- Berobenatide: The Monthly GLP-1 CandidateBerobenatide is an investigational ultra-long-acting GLP-1 receptor agonist designed for monthly dosing after weekly titration. Phase 2b data and what it means.
- PF-08653945: An Amylin Analogue Built for Monthly DosingPF-08653945, formerly MET-233i, is an investigational amylin analogue with a reported 19-day half-life, developed for monthly dosing alone and in combination.
- Why -41.7 and -4.5 Are the Same SizeWOMAC pain exists in a 0-20 and a 0-100 version. Two large incretin osteoarthritis trials used different ones, and the numbers are not comparable as printed.
- More Weight Lost, No More Pain RelievedIn TRIUMPH-4 the higher retatrutide dose arm lost more weight but relieved no more knee pain. Four readings of that result, and what it does not prove.